Celgene Defends Dismissal Of Cancer Drug Antitrust Suit
Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. urged the Second Circuit to uphold the dismissal of health plans' proposed antitrust class action alleging that the drugmaker fraudulently obtained patents for...To view the full article, register now.
Already a subscriber? Click here to view full article